Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients

Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Shuntaro, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954173/
https://www.ncbi.nlm.nih.gov/pubmed/31866617
http://dx.doi.org/10.3960/jslrt.19028
Descripción
Sumario:Methotrexate (MTX) is known as a first-line synthetic disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Although the risk of LPD development increases by RA inflammation itself, observation of spontaneous regression of LPD after MTX discontinuation lead to the theory of lymphomagenic role of MTX. In this review, we focused on the several immune response involved in LPD that developed under MTX administration in RA patients.

Ejemplares similares